Millions of Medicare beneficiaries who buy stand-alone prescription drug coverage could face steeper premium increases next year after a federal decision to let a temporary subsidy expire. The Centers for Medicare & Medicaid Services, under the Trump administration, confirmed it will not extend a demonstration program that had been holding down the cost of Part D drug plans. Independent analysts warn the change could push premiums higher for roughly half of the people enrolled in those plans, though the exact amounts will not be clear until final plan prices are published.
What the Part D premium-stabilization demonstration did
The program at the center of the decision is the Part D Premium Stabilization Demonstration, created to cushion premiums while the prescription-drug benefit was overhauled under the Inflation Reduction Act. As KFF explains, the demonstration cut the base beneficiary premium by a set amount each month, capped how much a plan’s premium could rise year over year, and narrowed the financial risk insurers took on. Those cushions kept sticker prices lower than they otherwise would have been while the benefit redesign phased in.
The subsidy was always temporary. It was structured as a demonstration, a mechanism CMS uses to test policy for a limited stretch rather than a permanent feature of the program. Its scheduled end at the close of the year removes the last of those cushions heading into the next plan year.
Free retirement updates: A quiet rule change can shrink your Social Security or Medicare check, and no one warns you. The free Retirement Shield newsletter catches these early and tells you what to do. Get it free.
Why CMS is letting the subsidy lapse
In announcing the 2027 Part D bid figures, CMS said drug-plan sponsors now have enough experience operating under the redesigned benefit to price their plans without the demonstration’s support. The agency framed the move as a return to ordinary market conditions, ending the program at the close of the current year so plans set premiums the traditional way. The reasoning and the underlying numbers are laid out in the agency’s Part D bid fact sheet.
Officials have argued that most beneficiaries will see only modest changes and that some plans could even come down in price. Outside analysts are less certain, because removing a subsidy that had been suppressing premiums generally works in one direction for the plans that leaned on it most.
Who could end up paying more
The impact falls on stand-alone Part D plans, the coverage that people with Original Medicare add for their prescriptions, rather than on the drug coverage bundled inside most Medicare Advantage plans. KFF’s assessment is that about half of stand-alone plan enrollees could see larger premium increases than they have grown used to in recent years. The word that matters is “could”: premiums vary widely by plan and region, so two neighbors on different plans may experience the change very differently.
For retirees on fixed incomes, even a modest monthly increase compounds across a year and stacks on top of other rising costs. The people most exposed are those who stay in the same plan out of habit without checking whether it remains competitively priced for the coming year.
How enrollees can limit the hit during open enrollment
The single most effective protection is comparison shopping during Medicare’s Annual Enrollment Period, which runs from October 15 to December 7. Plan premiums, formularies, and pharmacy networks are reset every year, so a plan that was a bargain one year can become an expensive outlier the next. The official plan finder lets enrollees enter their medications and compare the full cost of competing plans, not just the advertised premium.
Beneficiaries with limited income may also qualify for Extra Help, a federal program that lowers Part D costs and is unaffected by the demonstration’s end, and Medicare’s own overview of Part D coverage outlines how the pieces fit together. The end of the stabilization subsidy does not change the structure of the benefit itself, but it does raise the stakes on a decision many enrollees make on autopilot each fall.
This article was produced with AI assistance and reviewed by The Financial Wire editorial team.
More Financial Reading
- Bank statements: how long to keep them and when to toss them
- What really happens to your joint savings account when you die?
David M. Keller is a finance writer based in Columbus, Ohio, covering personal finance and consumer-focused economic topics. He earned his degree in journalism from Ohio University and began his career reporting on local business and economic trends for a regional media outlet. Since then, he has contributed to a variety of online publications, focusing on clear, practical coverage of topics such as cost of living, debt, and everyday financial decision-making.
